Clinical Trial Update: SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating SHR-A1811 in combination with Apatinib for advanced gastric cancer, gastroesophageal junction adenocarcinoma, and colorec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• SHR-A1811

Snippet

Sponsor: Yunpeng Liu | Conditions: Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING